Subscribe
Close
  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Renew

Takeda Pharmaceutical Plans Covington, Georgia, Plasma Plant

03/19/2019
Takeda Pharmaceutical Company Limited reported the United States Food and Drug Administration approved the company’s second submission for its new plasma manufacturing facility near Covington, Georgia.

The Georgia facility currently employs more than 1,000 full-time and contract employees, and continues to hire to fill additional roles in manufacturing, quality, engineering, maintenance, utilities, warehouse, and various support and facility roles.

According to company officials, the facility will produce FLEXBUMIN 25% [Albumin (Human), USP, 25% Solution; The medicine is indicated for hypovolemia, hypoalbuminemia, (burns, Adult Respiratory Distress Syndrome, and nephrosis, cardiopulmonary bypass surgery, and hemolytic disease of the newborn.

Albumin is not indicated as an intravenous nutrient. The Georgia facility received its first FDA approval, to manufacture GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% Solution, in June 2018, officials said.

“This latest approval is a significant milestone for the Georgia facility, Takeda and our patients,” said Thomas Wozniewski, Global Manufacturing & Supply Officer. “This new state-of-the-art facility is providing much needed additional capacity for meeting increasing global demand for plasma-derived therapies, and our team there will continue to scale up production over the coming years.”

“Following the acquisition of Shire, Takeda created a Business Unit dedicated to meeting the large and growing demand for plasma-derived products, essential for treating patients with a variety of rare, life-threatening, chronic and genetic diseases, said Julie Kim, President of Plasma-Derived Therapies at Takeda.

Our strategic focus and increased investment in plasma innovation and our world-class plasma collection and production capabilities will enable us to expand our broad, differentiated portfolio of medicines and serve more patients. Our Georgia facility is a key part of these plans,” added Julie Kim.

Share

Exclusive Research